Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.46 |
| ▸ | NPY1R | P25929 | 7/20 | 0.46 |
| ▸ | NPY2R | P49146 | 5/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.43 |
| ▸ | FCER2 | P06734 | 1/20 | 0.41 |
| ▸ | TRHDE | Q9UKU6 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pabetan SCHEMBL14928984 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| Pabetan SCHEMBL21571465 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| Pabetan SCHEMBL29894618 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL8341764 | 0.91 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5REPHX1 | |
| SCHEMBL27352129 | 0.91 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5REPHX1 | |
| SCHEMBL7850376 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL7859111 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL7850373 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL7859109 | 0.89 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL7857092 | 0.88 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| US-6251869-B1 | SUCH AS L-PHENYLALANYL-L-ARGINYL-BETA-NAPHTHYLAMIDE; FOR TREATING GRAM-NEGATIVE ORGANISMS INFECTIONS IN MAMMALS | PHARMACIA & UPJOHN COMPANY | 2001-06-26 | — | — | US | claimed |
| EP-1077718-A1 | ENHANCEMENT OF OXAZOLIDINONE ANTIBACTERIAL AGENTS ACTIVITY BY ARGININE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999059616-A1 | ENHANCEMENT OF OXAZOLIDINONE ANTIBACTERIAL AGENTS ACTIVITY BY USING ARGININE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-25 | — | — | WO | claimed |
| EP-0554314-B1 | A METHOD OF DETERMINING PORPHYROMONAS GINGIVALIS | WIKSTROEM MAUDE BIRGITTA (SE) | 1996-08-14 | — | — | EP | claimed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2022046997-A1 | BAMA-BINDING AGENTS AND METHODS OF USE THEREOF | NGM BIOPHARMACEUTICALS, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20190352339-A1 | PEPTIDE INHIBITOR OF TRANSMEMBRANE PORE FORMATION AND EFFLUXPUMP FUNCTION IN A SMALL MULTIDRUG RESISTANCE PROTEIN FROM PSEUDOMONAS AERUGINOSA | HOSPITAL FOR SICK CHILDREN (CA) | 2019-11-21 | — | — | US | disclosed |
| EP-2987787-A1 | NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY | Juntendo Educational Foundation (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-9115169-B2 | Method of treating tumors | LYTIX BIOPHARMA AS (NO) | 2015-08-25 | — | — | US | disclosed |
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2012-05-03 | — | — | US | disclosed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | disclosed |
| WO-1999059616-A1 | ENHANCEMENT OF OXAZOLIDINONE ANTIBACTERIAL AGENTS ACTIVITY BY USING ARGININE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5981164-A | RAPID AND SIMPLE DIAGNOSIS OF PERIODONTITIS BY REACTING SAMPLE WITH SUBSTRATE FOR TRYPSIN-LIKE AMIDASE, A MARKER SYSTEM, AND A MONO- OR DIPEPTIDE ENHANCER CONTAINING GLYCINE DERIVATIVE; ANALYZING MIXTURE FOR SIGNAL GENERATED BY MARKER | WIKSTROEM MAUDE BIRGITTA (SE) | 1999-11-09 | — | — | US | disclosed |
| EP-0554314-B1 | A METHOD OF DETERMINING PORPHYROMONAS GINGIVALIS | WIKSTROEM MAUDE BIRGITTA (SE) | 1996-08-14 | — | — | EP | disclosed |
| EP-0554314-A1 | A METHOD OF DETERMINING PORPHYROMONAS GINGIVALIS. | WIKSTROEM MAUDE BIRGITTA (SE) | 1993-08-11 | — | — | EP | disclosed |
| EP-0255341-B1 | REAGENT FOR TESTING PERIODONTAL DISEASES | SUNSTAR KABUSHIKI KAISHA (JP) | 1993-02-03 | — | — | EP | disclosed |
| US-5137811-A | Method for diagnosing periodontal diseases with a substrate specific for aminopeptidase activity of periodontopathic bacteria | SUNSTAR KABUSHIKI KAISHA (JP) | 1992-08-11 | — | — | US | disclosed |
| WO-1992007086-A1 | A METHOD OF DETERMINING PORPHYROMONAS GINGIVALIS | WIKSTROEM MAUDE BIRGITTA (SE) | 1992-04-30 | — | — | WO | disclosed |
| EP-0255341-A2 | Reagent for testing periodontal diseases | SUNSTAR KABUSHIKI KAISHA (JP) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | NPY4R 2699/4885NPY1R 2746/4885NPY2R 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.